Researchers systematically reviewed 51 studies to characterize the clinical features, timeline, and outcomes of dupilumab-related cutaneous T-cell lymphomas (CTCL) in patients with atopic dermatitis and develop consensus-based recommendations for dupilumab use in these settings. Data from 547 patients (mean age, 58 years) showed that new or worsening skin lesions developed at a mean of 8.9 months after dupilumab initiation. Mycosis fungoides (MF) was diagnosed in 72% of cases, Sézary syndrome (SS) in 11%, and other CTCL subtypes in 19%, of which 53% were at an early stage. Dupilumab was discontinued in 75% of cases, while 62% received CTCL-directed treatment.
Clinical remission was achieved in 44 of the 63 patients with available follow-up. Consensus recommendations by an expert panel Dupilumab may unmask or exacerbate pre-existing CTCL. Dupilumab should be avoided in cases of MF/SS and…
